ReviewCurrent diabetes reports2018
Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field.
Review in Current diabetes reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- A Clinical Nomogram Based on the Triglyceride-Glucose Index to Predict Contrast-Induced Acute Kidney Injury after Percutaneous Intervention in Patients with Acute Coronary Syndrome with Diabetes Mellitus.Cardiovascular therapeutics · 2022Trial
- Blood Pressure Control and the Association With Diabetes Mellitus Incidence: Results From SPRINT Randomized Trial.Hypertension (Dallas, Tex. : 1979) · 2020Trial
- Revisiting Insulin Resistance in the Pathophysiology of Type 2 Diabetes Mellitus: A Multi-Organ Perspective.Diabetes & metabolism journal · 2026Review
- Associations of the triglyceride-glucose index, triglyceride glucose-body mass index, waist-triglyceride index and modified triglyceride-glucose indices with mortality in cardiovascular-kidney-metabolic syndrome stages 0-4: Evidence from NHANES 1999-2020.Journal of translational internal medicine · 2026Article
- Triglyceride-glucose index association with kidney function in adults; a population-based study.BMC endocrine disorders · 2025Article
- The combined prognostic effect of the triglyceride-glucose index and estimated glucose disposal rate on long-term mortality among individuals with cardiovascular-kidney-metabolic syndrome stages 0-3.BMC cardiovascular disorders · 2025Article
- Article
- Association of estimated glucose disposal rate with chronic kidney disease: comparative analysis against traditional insulin resistance indices.Frontiers in endocrinology · 2025Article
- Association between triglyceride-glucose index and sarcopenia in patients with chronic kidney disease.Frontiers in endocrinology · 2025Article
- Association between the triglyceride-glucose index and in-hospital major adverse cardiovascular events in patients with acute coronary syndrome: results from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome project.Cardiovascular diabetology · 2024Observational
- Comparison of TyG and Newly TyG Related Indicators for Chronic Kidney Diseases Estimation in a Chinese Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Article
- Relationship between the longitudinal trajectory of the triglyceride-glucose index and the development of CKD: an 8-year retrospective longitudinal cohort study.Frontiers in endocrinology · 2024Article
- The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease.Cardiovascular diabetology · 2023Article
- Association of triglyceride-glucose index with coronary severity and mortality in patients on dialysis with coronary artery disease.European journal of medical research · 2023Article
- Exercise and chronic kidney disease: potential mechanisms underlying the physiological benefits.Nature reviews. Nephrology · 2023Review
- Association between triglyceride-glucose index and risk of end-stage renal disease in patients with type 2 diabetes mellitus and chronic kidney disease.Frontiers in endocrinology · 2023Article
- Prognostic Nutritional Index Combined with Triglyceride-Glucose Index to Contrast a Nomogram for Predicting Contrast-Induced Kidney Injury in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome After Percutaneous Coronary Intervention.Clinical interventions in aging · 2023Article
- Article
- Comparison of Novel Metabolic Indices in Estimation of Chronic Kidney Diseases in a Southern Chinese Population.Diabetes, metabolic syndrome and obesity : targets and therapy · 2020Article
- Theaflavins Improve Insulin Sensitivity through Regulating Mitochondrial Biosynthesis in Palmitic Acid-Induced HepG2 Cells.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewInsulin resistance is an early complication of chronic kidney disease (CKD) associated with worsening cardiovascular outcomes. This review will evaluate mechanisms responsible for CKD-induced insulin resistance and therapies currently available. RECENT
findingsRecent mechanisms have been identified including SIRPα and specific E3 ubiquitin ligases causing insulin resistance in CKD. The hallmark finding in these mechanisms is degradation of the insulin receptor substrate 1 (IRS1) which impairs intracellular insulin signaling and ultimately metabolism. The mechanisms responsible for insulin resistance in CKD include inflammation, oxidative stress, elevations in aldosterone, angiotensin II, uremic toxins, and metabolic acidosis. Potential treatments currently available for CKD-induced insulin resistance include lifestyle modification and metformin. Potential future treatments may include glucagon-like peptide agonists, SGLT2 inhibitors, and thiazolidinediones. Investigations into molecular mechanisms responsible for insulin resistance in CKD may provide new therapeutic targets while current therapies may prevent the catabolic sequelae of CKD and ameliorate its cardiovascular consequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.